Agios Pharmaceuticals, Inc. AGIO
Analyst Ratings
- Consensus
- Moderate Buy — 5 Buy · 3 Hold · 0 Sell (8 analysts)
- Avg. Price Target
- $41.50 (+12.2% upside)
Key Stats
- Today's Range
- $36.10 – $37.32
- 50-Day Range
- $29.67 – $37.74
- 52-Week Range
- $22.24 – $46.00
- Volume
- 913K shs
- Average Volume
- 1.17 million shs
- Market Cap
- $2.21 billion
- P/E Ratio
- —
- Dividend Yield
- —
Short Interest
- Short Interest
- 10.63%
- Days to Cover
- 22.78
About Agios Pharmaceuticals, Inc.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.
Related Stocks
Compare head-to-head: AGIO vs LLY·AGIO vs JNJ·AGIO vs ABBV·AGIO vs ABT
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.